GlassScriptPhysician profile
Harry P Claybrook
NPI 1801892765
$9,261.79
in general payments reported to CMS, 2019-2025
43 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,376 · 2020: $1,368 · 2021: $1,439 · 2022: $1,289 · 2023: $1,235 · 2024: $1,212 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,789.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,288.35 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $990.02 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $766.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $668.69 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $634.25 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $525.47 | 2019-2025 | Trintellix |
| Pfizer INC. | $483.43 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $445.50 | 2019-2023 | |
| Corium, LLC | $351.86 | 2023-2024 | Azstarys |
| Lilly USA, LLC | $349.80 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Amarin Pharma, INC. | $278.94 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $217.62 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $210.50 | 2019-2024 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.85 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Kowa Pharmaceuticals America, INC. | $200.06 | 2019-2025 | Zoryve |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $179.91 | 2020-2023 | Nexletol |
| Daiichi Sankyo INC. | $168.48 | 2022-2025 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $148.44 | 2022 | |
| Allergan, INC. | $139.31 | 2020 | |
| Merck Sharp & Dohme LLC | $126.47 | 2020-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Axsome Therapeutics, INC. | $121.82 | 2023-2025 | Auvelity, Symbravo |
| Otsuka America Pharmaceutical, INC. | $88.12 | 2022-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $76.92 | 2022-2025 | Quviviq, Quviviq |
| Arbor Pharmaceuticals, INC. | $61.46 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $59.52 | 2020-2021 | |
| Kaleo, INC. | $48.30 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $46.85 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $46.23 | 2023 | Gvoke Hypopen |
| Dexcom, INC. | $41.36 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.92 | 2021 | |
| Exact Sciences Corporation | $29.14 | 2025 | The Cologuard Plus Collection Kit |
| Inogen, INC. | $26.74 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $26.70 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $24.03 | 2021 | |
| Inspire Medical Systems, INC. | $23.13 | 2025 | Inspire |
| Fisher & Paykel Healthcare INC | $19.63 | 2024 | Fisher & Paykel Healthcare |
| Genentech USA, INC. | $17.87 | 2019 | |
| Baxter Healthcare | $17.10 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Eisai INC. | $17.00 | 2022 | |
| Antares Pharma, INC. | $16.19 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.37 | 2025 | Voquezna |
| Sanofi Pasteur INC. | $11.91 | 2019 | |
| Currax Pharmaceuticals LLC | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Claybrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.